Zobrazeno 1 - 7
of 7
pro vyhledávání: '"feryel ksontini"'
Autor:
Mariem Ben Rekaya, Feryel Ksontini, Linda Bel Haj Kacem, Farah Sassi, Emna Harigua‐Souiai, Ryma Boujneh, Ahmed H'mayada, Yosra Zaimi, Mouna Ayadi, Mediha Trabelsi, Ridha Mrad, Soumaya Rammeh
Publikováno v:
Clinical Case Reports, Vol 11, Iss 6, Pp n/a-n/a (2023)
Key clinical message We report the first case of pathologic complete response (pCR) to neoadjuvant imatinib in a gastric stromal tumor harboring KIT mutations in both exons 11 and 9. The significance of this co‐occurrence is unknown and might incre
Externí odkaz:
https://doaj.org/article/348465859f9f47bca3a3dbc9997dbcd1
Autor:
Olivier Caliez, Daniel Pietrasz, Feryel Ksontini, Solène Doat, Jean-Marc Simon, Jean-Christophe Vaillant, Valerie Taly, Pierre Laurent-Puig, Jean-Baptiste Bachet
Publikováno v:
Digestive and Liver Disease
Digestive and Liver Disease, 2022, 54 (10), pp.1428-1436. ⟨10.1016/j.dld.2022.01.126⟩
Digestive and Liver Disease, 2022, 54 (10), pp.1428-1436. ⟨10.1016/j.dld.2022.01.126⟩
International audience; Background: prognostic biomarkers could be useful to better select patients with borderline resectable (BR) or locally advanced (LA) pancreatic adenocarcinoma (PA) for chemoradiotherapy (CRT) and/or secondary resection.Aims: T
Autor:
Ines lajnef, feryel ksontini, Zakaria Saied, Yosr Zenzri, mohamed chaabouni, mouna ayadi, henda raies
This report describes a case of anti-hu antibody associated paraneoplastic sensory neuropathy with an undifferentiated lung tumor . The aim of this case was to highlight the importance of a multidisciplinary team approach for early recognition and ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eab92cc0e229286257f2ab581f50fe1
https://doi.org/10.22541/au.167810319.91334280/v1
https://doi.org/10.22541/au.167810319.91334280/v1
Autor:
Ehsen Ben Brahim, Hakim Zenaidi, Hend Ben Néji, Abdelwahed Yahmadi, Fatma Khanchel, Aschraf Chadli, Imen Helal, Raja Jouini, Raweh Hedhili, Feryel Ksontini
Publikováno v:
General Thoracic and Cardiovascular Surgery
SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a recently identified aggressive subtype of sarcoma. We present the case of a 44-year-old man who underwent a surgery for a perforated small intestine. Compued tomography scan revealed a tissular me
Autor:
E. Fabiano, Léo Mas, Romain Coriat, Angélique Saint, Nicolas Williet, Thierry Lecomte, Feryel Ksontini, Julien Taieb, Eric Francois, Jean-Baptiste Bachet, Lysiane Marthey, Angélique Vienot, David Tougeron, Matthieu Sarabi, Raef Abdallah, Vincent Hautefeuille, Christelle De La Fouchardiere, J. Forestier, Edouard Auclin, Florence Leroy, Antonio Sa Cunha
Publikováno v:
Br J Cancer
BACKGROUND: FOLFIRINOX has shown promising results in locally advanced (LAPA) or borderline resectable (BRPA) pancreatic adenocarcinoma. We report here a cohort of patients treated with this regimen from the AGEO group. METHODS: This is a retrospecti
Autor:
Pascal Hammel, Paul McLellan, Daniel Pietrasz, Dewi Vernerey, Feryel Ksontini, Solene Doat, Julie Henriques, Jérôme Desramé, Isabelle Trouilloud, Christophe Louvet, Jean-Baptiste Bachet
Publikováno v:
Clinics and Research in Hepatology and Gastroenterology
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2021, 45 (3), pp.101541. ⟨10.1016/j.clinre.2020.08.016⟩
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2021, 45 (3), pp.101541. ⟨10.1016/j.clinre.2020.08.016⟩
International audience; In metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of poor prognosis. The prognostic role of baseline NLR and NLR change during first-line chemotherapy were determined
Autor:
M. Collins, Lysiane Marthey, R. Abdallah, Julien Taieb, A-L. Pointet, E. Francois, J-B. Bachet, Florence Leroy, A. Sa Cunha, David Tougeron, Thierry Lecomte, Romain Coriat, Vincent Hautefeuille, Edouard Auclin, Léo Mas, J. Forestier, Feryel Ksontini, Nicolas Williet, Angélique Vienot
Publikováno v:
Annals of Oncology. 30:v260
Background FOLFIRINOX has shown promising results in LA or BR pancreatic adenocarcinoma (PA) in non-randomized series. We report here an updated large cohort of pts treated with FOLFIRINOX for a LA or BR PA. Methods This French retro-prospective mult